Horizons in World Cardiovascular Research. Volume 26 (Horizons in World Cardiovascular Research Series)

This book is a compilation of ten chapters in Cardiovascular research from around the world. Chapter One starts off with ß -blockers and their use in the prevention of acute cardiac events. Chapter Two focuses on the emerging roles of extracellular chaperones and some of their associated cochaperones in cardiovascular disease and the appealing prospect for the development of novel pharmacotherapeutic strategies against the disease by targeting these complexes. The authors in Chapter Three review of previous trials suggest that coronary revascularization significantly reduces mortality and myocardial infarction rates in patients with stable coronary artery disease and moderate-to-severe ischemia. In Chapter Four, the authors provide diagnosis, risk factors and the management of heart failure with preserved ejection fraction. The objective of Chapter Five is to include the most current findings on the cellular pathophysiology of HFpEF and HFpEF-related comorbidities that are being discovered, which might eventually lead to more patient-specific medicines with clinical significance. In Chapter Six the authors describe the short-term clinical courses of seven hemodialysis patients receiving sacubitril-valsartan, as well as the long-term clinical courses of two anuric hemodialysis patients with reduced left ventricular ejection fractions after aortic valve replacement for aortic stenosis who showed improvement in cardiac function after the administration of sacubitril-valsartan. Chapter Seven speaks about the current issues in total arterial revascularization. Chapter Eight goes on to cover the advances in technology and interpretation software that have occurred in recent years. Chapter Nine highlights the significant transformations that monitoring systems have endured over history with details on the recording technique. The goal of the last chapter was to assess the prevalence of asymptomatic heart failure with preserved ejection fraction (HFpEF) in subjects at high risk of developing heart failure and to define the diagnostic accuracy of (N-terminal pro-B-type natriuretic peptide (NT-pro BNP) assay compared with echocardiography in this setting.